SPOTLIGHT: Erbitux gets first-line status

by admin |


The cancer drug Erbitux can be marketed as a first-line treatment for colon cancer, now that the FDA has OK'd a label change. The drug is made and marketed by ImClone Systems and Bristol-Myers Squibb. Release

Suggested Articles

Pfizer headquarters logo sign
Pharma

Pfizer eyes Roche blockbusters with 3 biosim launches

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

by Eric Sagonowsky
Novo Nordisk
Pharma

NICE shuns Novo Nordisk's obesity med Saxenda

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

by Kyle Blankenship
tecentriq
Marketing

Roche's Tecentriq flops another bladder cancer trial

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.

by Angus Liu